These alterations underscore critical pathways contributing to DLBCL-type RT, including chromatin regulation, splicing, c-MYC activation, NF- κB signaling, immune evasion, inflammation, apoptosis resistance, DNA damage response, and cell-cycle dysregulation. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.